ubtenon’ depot corticoteroid injection in patient with a hitory of corticoteroid-induced intraocular preure elevation

PURPOE: To determine whether a hitory of intraocular preure elevation from local corticoteroid adminitration could predict ubequent intraocular preure elevation after poterior ubtenon’ corticoteroid injection. METHOD: A retropective review wa performed of 64 conecutive patient (64 eye) receiving poterior ubtenon’ corticoteroid injection. Patient were categorized a either hitorical corticoteroid reponder or nonreponder baed on intraocular preure repone to topical corticoteroid drop in the ame eye or to previou poterior ubtenon’ corticoteroid injection of the fellow eye. Hitorical reponder were defined a having a relative intraocular preure increae of 5 mm Hg and abolute intraocular preure greater than 24 mm Hg with an anatomically open angle. Relative rik of intraocular preure elevation wa evaluated baed on hitorical repone and preenting diagnoi. REULT: Nine eye were hitorical reponder, and 55 eye were hitorical nonreponder. A higher rate of recurrent intraocular preure elevation developed in hitorical reponder eye (4 of 9, 44%) compared with nonreponder (7 of 55, 13%) after poterior ubtenon’ injection (P = .04, Fiher’ tet; P = .07, Kaplan-Meier analyi). Hitorical reponder with uveiti were at ignificantly higher rik of intraocular preure elevation than nonreponder without uveiti (hazard RATIO = 10.8, P = .04, Cox proportional hazard). All but one eye that developed intraocular preure elevation from poterior ubtenon’ injection wa adequately controlled with topical antiglaucoma therapy. CONCLUION: In nonglaucomatou eye, a previou hitory of corticoteroid-induced intraocular preure elevation i a relative, not abolute, contraindication to poterior ubtenon’ corticoteroid injection, becaue the rik of intraocular preure elevation i not abolute, and becaue it can uually be well controlled with topical antiglaucoma therapy.